224 related articles for article (PubMed ID: 19903806)
81. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
[TBL] [Abstract][Full Text] [Related]
82. A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening.
Patanwala IY; Bauer HM; Miyamoto J; Park IU; Huchko MJ; Smith-McCune KK
Am J Obstet Gynecol; 2013 May; 208(5):343-53. PubMed ID: 23159693
[TBL] [Abstract][Full Text] [Related]
83. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
84. [Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR].
Sahiner F; Gümral R; Sener K; Yiğit N; Dede M; Yapar M; Kubar A
Mikrobiyol Bul; 2012 Oct; 46(4):624-36. PubMed ID: 23188576
[TBL] [Abstract][Full Text] [Related]
85. Testing for cervical cancer: new recommendations from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology.
CA Cancer J Clin; 2012; 62(3):211-2. PubMed ID: 22418892
[No Abstract] [Full Text] [Related]
86. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus.
Dalstein V; Riethmuller D; Sautière JL; Prétet JL; Kantelip B; Schaal JP; Mougin C
Eur J Cancer; 2004 May; 40(8):1225-32. PubMed ID: 15110887
[TBL] [Abstract][Full Text] [Related]
87. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women.
Nobbenhuis MA; Helmerhorst TJ; van den Brule AJ; Rozendaal L; Jaspars LH; Voorhorst FJ; Verheijen RH; Meijer CJ
J Clin Pathol; 2002 Jun; 55(6):435-9. PubMed ID: 12037026
[TBL] [Abstract][Full Text] [Related]
88. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice.
Armah H; Austin RM; Dabbs D; Zhao C
Arch Pathol Lab Med; 2009 Sep; 133(9):1426-30. PubMed ID: 19722749
[TBL] [Abstract][Full Text] [Related]
89. Toward objective cervical cancer screening: maybe the eyes do have it.
Stoler MH
Am J Clin Pathol; 2010 Jul; 134(1):5-6. PubMed ID: 20551259
[No Abstract] [Full Text] [Related]
90. HPV test shows low sensitivity of Pap screen in older women.
Gyllensten U; Lindell M; Gustafsson I; Wilander E
Lancet Oncol; 2010 Jun; 11(6):509-10; author reply 510-1. PubMed ID: 20522375
[No Abstract] [Full Text] [Related]
91. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.
Fait G; Kupferminc MJ; Daniel Y; Geva E; Ron IG; Lessing JB; Bar-Am A
Gynecol Oncol; 2000 Nov; 79(2):177-80. PubMed ID: 11063640
[TBL] [Abstract][Full Text] [Related]
92. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
93. Cervical HPV testing versus cytology.
Burki TK
Lancet Oncol; 2018 Aug; 19(8):e390. PubMed ID: 30017347
[No Abstract] [Full Text] [Related]
94. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
[TBL] [Abstract][Full Text] [Related]
95. Human papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing?
Feldman S
JAMA Intern Med; 2014 Oct; 174(10):1539-40. PubMed ID: 25069413
[No Abstract] [Full Text] [Related]
96. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
Fait G; Daniel Y; Kupferminc MJ; Lessing JB; Niv J; Bar-Am A
Gynecol Oncol; 1998 Sep; 70(3):319-22. PubMed ID: 9790781
[TBL] [Abstract][Full Text] [Related]
97. [Human papillomavirus and screening for cervical cancer: state of art and prospects].
Meijer CJ; Rozendaal L; Voorhorst FJ; Verheijen R; Helmerhorst TJ; Walboomers JM
Ned Tijdschr Geneeskd; 2000 Aug; 144(35):1675-9. PubMed ID: 10981235
[TBL] [Abstract][Full Text] [Related]
98. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
99. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings.
Cox JT
JAMA; 1999 May; 281(17):1645-7. PubMed ID: 10235161
[No Abstract] [Full Text] [Related]
100. Cervical cancer screening in the early post vaccine era.
Waxman AG
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
